產品詳情
僅用于工業(yè)應用或科學研究,不可用于人類或動物的臨床診斷或治療,非藥用. Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.